Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Mabwell (Shanghai) Bioscience / Equity Capital Markets

<ul>
<li>Mabwell raised HKD 1302m (USD 166m) from its global offering and will list on the Hong Kong Stock Exchange on Tuesday April 27th, 2026.</li>
<li>In our previous note, we looked at the company's fundamentals and the valuation.</li>
<li>In this note, we provide an update for the IPO before its trading debut.</li>
</ul>


Mabwell raised HKD 1302m (USD 166m) from its global offering and will list on the Hong Kong Stock Exchange on Tuesday April 27th, 2026.
In our previous note, we looked at the company's fundamentals and the valuation.
In this note, we provide an update for the IPO before its trading debut.


<ul>
<li>Mabwell, a China-based biotech, launched its IPO to raise at least USD 185 million via a Hong Kong listing.</li>
<li>In this note, we look at the deal terms and provide our thought of valuation for the company.</li>
<li>We analyzed the reference connect events and assess the risk-reward of the deal.</li>
</ul>


Mabwell, a China-based biotech, launched its IPO to raise at least USD 185 million via a Hong Kong listing.
In this note, we look at the deal terms and provide our thought of valuation for the company.
We analyzed the reference connect events and assess the risk-reward of the deal.


Mabwell (迈威生物) A+H: Moderate Upside but Connect Event Ahead

Quantitative Analysis

<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of April 17th.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.</li>
<li>We highlight flows for Pop Mart Intl, China Life, Tencent, Xiaomi, SMIC, YOFC, CCB, China Hongqiao, Ping An Insurance.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of April 17th.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.
We highlight flows for Pop Mart Intl, China Life, Tencent, Xiaomi, SMIC, YOFC, CCB, China Hongqiao, Ping An Insurance.


HK Connect Flows Weekly (Apr 17th): Pop Mart Intl, China Life, Tencent, Xiaomi, SMIC, YOFC, CCB

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<ul>
<li>The high revenue growth in 2025 was mainly driven by one-time upfront payment in licensing deals, which is unsustainable. If future external cooperation weakens, the revenue scale will shrink significantly.</li>
<li>Compared with the peak sales forecast in the 2022 prospectus of Mabwell in SSE Star Market, the actual revenue from Mabwell's sales of drugs in 2025 was significantly below expectations. </li>
<li>Therefore, we prefer a conservative IPO pricing. For example, we think valuation of Mabwell would be lower than peers such as Remegen, Junshi, Kelun Bio, CSPC.</li>
</ul>


The high revenue growth in 2025 was mainly driven by one-time upfront payment in licensing deals, which is unsustainable. If future external cooperation weakens, the revenue scale will shrink significantly.
Compared with the peak sales forecast in the 2022 prospectus of Mabwell in SSE Star Market, the actual revenue from Mabwell's sales of drugs in 2025 was significantly below expectations. 
Therefore, we prefer a conservative IPO pricing. For example, we think valuation of Mabwell would be lower than peers such as Remegen, Junshi, Kelun Bio, CSPC.


Pre-IPO Mabwell (Shanghai) Bioscience (PHIP Updates) - Some Points Worth the Attention

Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hansoh-pharmaceutical-group-co" target="_blank" data-smartkarma-citation="entities:23675:1" rel="noopener">Hansoh Pharmaceutical Group (3692 HK)</a> has announced 2025 result, with net profit increasing 27% YoY to RMB6B, beating market expectations, on 23% YoY revenue growth to RMB15B.</li>
<li>In 2025, revenue of innovative medicines increased 30% YoY to RMB12B and accounted for 82% (2024: 77%) of the revenue, becoming a core driver for sustainable growth.</li>
<li>Along with providing long-term revenue visibility, innovative pipeline is well-positioned to proactively seize opportunities for out-licensing and collaboration, enabling the company to explore the ex-China commercialization potential of its pipeline.</li>
</ul>



Hansoh Pharmaceutical Group (3692 HK) has announced 2025 result, with net profit increasing 27% YoY to RMB6B, beating market expectations, on 23% YoY revenue growth to RMB15B.
In 2025, revenue of innovative medicines increased 30% YoY to RMB12B and accounted for 82% (2024: 77%) of the revenue, becoming a core driver for sustainable growth.
Along with providing long-term revenue visibility, innovative pipeline is well-positioned to proactively seize opportunities for out-licensing and collaboration, enabling the company to explore the ex-China commercialization potential of its pipeline.


Hansoh Pharmaceutical (3692 HK): Innovative Drugs and BD Momentum Drive 2025 Performance

China

RemeGen is a China-based biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on therapeutic antibody drugs, including antibody-drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies, for major diseases such as autoimmune disorders, oncology, and ophthalmology. Key products include Telitacicept (RC18) and Disitamab Vedotin (RC48). RemeGen was co-founded in 2008 and is headquartered in Yantai, Shandong Province, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

RemeGen (9995 HK)

Mabwell (迈威生物) A+H IPO Trading

Mabwell A+H is set to start trading on April 28. We update deal dynamics, recap valuation, and reference peers. We think the deal will be...

Ke Yan, CFA, FRM

Mabwell (迈威生物) A+H: Moderate Upside but Connect Event Ahead

Mabwell A+H: China biotech IPO with a near-term Phase III catalyst, but both lead indications face meaningful competitive headwinds. Moderate...

Ke Yan, CFA, FRM

HK Connect Flows Weekly (Apr 17th): Pop Mart Intl, China Life, Tencent, Xiaomi, SMIC, YOFC, CCB

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Pop Mart Intl, China Life, Tencent, Xiaomi, SMIC, YOFC,...

Ke Yan, CFA, FRM

Pre-IPO Mabwell (Shanghai) Bioscience (PHIP Updates) - Some Points Worth the Attention

Mabwell's commercialization progress is significantly below expectations. If future external cooperation weakens, revenue scale will shrink...

Xinyao (Criss) Wang

Hansoh Pharmaceutical (3692 HK): Innovative Drugs and BD Momentum Drive 2025 Performance

Hansoh beats expectations with 27% YoY net profit growth to RMB6B in 2025, on 23% YoY revenue growth to RMB15B. Innovative medicines revenue...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Mabwell (迈威生物) A+H IPO Trading

​Mabwell A+H is set to start trading on April 28. We update deal dynamics, recap valuation, and reference peers. We think the deal will be...

Ke Yan, CFA, FRM

Mabwell (迈威生物) A+H: Moderate Upside but Connect Event Ahead

Mabwell A+H: China biotech IPO with a near-term Phase III catalyst, but both lead indications face meaningful competitive headwinds. Moderate...

Ke Yan, CFA, FRM

HK Connect Flows Weekly (Apr 17th): Pop Mart Intl, China Life, Tencent, Xiaomi, SMIC, YOFC, CCB

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Pop Mart Intl, China Life, Tencent, Xiaomi, SMIC, YOFC,...

Ke Yan, CFA, FRM

Pre-IPO Mabwell (Shanghai) Bioscience (PHIP Updates) - Some Points Worth the Attention

Mabwell's commercialization progress is significantly below expectations. If future external cooperation weakens, revenue scale will shrink...

Xinyao (Criss) Wang

Hansoh Pharmaceutical (3692 HK): Innovative Drugs and BD Momentum Drive 2025 Performance

​Hansoh beats expectations with 27% YoY net profit growth to RMB6B in 2025, on 23% YoY revenue growth to RMB15B. Innovative medicines revenue...

Tina Banerjee

Mabwell A+H is set to start trading on April 28. We update deal dynamics, recap valuation, and reference peers. We think the deal will be...

Hansoh beats expectations with 27% YoY net profit growth to RMB6B in 2025, on 23% YoY revenue growth to RMB15B. Innovative medicines revenue...